Sarepta Therapeutics, Inc.

36.10 -0.85(-2.30%) Date:

Sarepta Therapeutics, Inc.

Sarepta Therapeutics Inc. (SRPT): 4Q Dystrophin Data A Key Catalyst

Morgan Stanley sees Clean beat with no red flags; expect SRPT up 5-10%

Sarepta Therapeutics Inc (SRPT): Solid New CEO

With a new CEO in place, the firm would expect lingering concerns from prior CEO Kaye's stepping aside to be assuaged

Sarepta Therapeutics Inc (NASDAQ:SRPT) Raised Guidance To $95M As The Launch Continues To Look Highly Encouraging

Credit Suisse’s new 2017 estimate is $103M which is higher than its previous estimate of $89M

Sarepta Therapeutics Inc (SRPT): Exondys 51 Prescriber And Patient Base Grow

Despite continued worry around the launch, docs estimate that prescribing has almost doubled since the firm’s last survey